stockrow
Saturday 7 November 2026
Export ICCC’s income statement to Excel — free account
ImmuCell Corporation
ICCC Healthcare Biotechnology
ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024.
- Revenue
- +11.5%
- EPS
- +233.3%
- Free cash flow
- +54.9%
- Total debt
- −15.3%
Quarter to June 2026, against a year earlier
9.90
0.05
−0.50%
Follow ICCC
Alert me
ImmuCell Corporation (ICCC) P/E ratio
As of 6 November 2026, ImmuCell Corporation (ICCC) trades at a P/E ratio of 117×. Over the past ten years it has ranged from 0.0× (June 2026) to 1,444× (August 2022); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 10.6× and above the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 43.2× | 129.06% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 119× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 23.6× | (35.52%) |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1,444×
Ten-year median
0.0×
Current reading's percentile
71
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CBUS Cibus, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| VANI Vivani Medical, Inc. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| PLYX Polaryx Therapeutics, Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| VXRT VAXART, INC. compare | 2.8× |
| ICCC ImmuCell Corporation | 117× |
| RTSN Retension Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)